


3

IN THE CLAIMS:


Please cancel claims 2-11 without prejudice to or disclaimer of their subject matter. Please amend claim 1 to read as follows, and add the following new claims 12-31.

- B2 1. (once amended) A process for the production of a compound of formula (I), or a pharmaceutically acceptable salt and/or hydrate thereof:




(I)

wherein R is C<sub>1-4</sub> alkyl or C<sub>1-4</sub> haloalkyl, which comprises reaction of a compound of formula (II):



(II)

wherein X is a leaving group; with a compound of formula (III):



(III)


B3  
cont

wherein R is as defined for formula (I), or a salt thereof;  
in the presence of a base and an aqueous solvent, wherein the solvent is  
water;  
and optionally forming a pharmaceutically acceptable salt and/or hydrate  
thereof.

---


- B3
12. The process according to claim 1 wherein 10 volumes of solvent based on the compound of formula (II) are used.
13. The process according to claim 1 wherein between 1.01 and 1.08 mole equivalents of the compound of formula (III) based on the compound of formula (II) are used.
14. The process according to claim 1 performed at a temperature between ambient and about 60°C.
15. The process according to claim 1 wherein the base is triethylamine, diisopropylamine, pyridine, N,N-dimethylaniline, N,N-dimethylaminopyridine, 1,8-diazabicyclo[5.4.0]undec-7-ene, 1,4-diazabicyclo[2.2.2]octane, or a tetraC<sub>1-6</sub>alkylammonium hydroxide.
16. The process according to claim 1 wherein the base is triethylamine or a tetraC<sub>1-6</sub>alkylammonium hydroxide.
17. The process according to claim 1 wherein the base is triethylamine.
18. The process according to claim 1 wherein between 3.2 and 3.8 mole equivalents of base is used based on the compound of formula (II), and wherein the compound of formula (III) is in the form of the dimethanesulfonate salt, the hydrochloride salt, the trifluoroacetate salt, or the sulfate salt.

- B3  
cont
19. The process according to claim 1 wherein X is chloro.
20. The process according to claim 1 wherein the compound of formula (III) is 4-aminomethyl-3-methoxyiminopyrrolidinium dimethanesulfonate.
21. The process according to claim 1 wherein R is C<sub>1</sub> alkyl.
22. The process according to claim 1 wherein the compound of formula (I) is (R,S)-7-(3-aminomethyl-4-syn-methoxyimino-pyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid methanesulfonate or a hydrate thereof.
23. A process for the production of a compound of formula (I), or a pharmaceutically acceptable salt and/or hydrate thereof:




(I)

wherein R is C<sub>1-4</sub> alkyl or C<sub>1-4</sub> haloalkyl, which comprises reaction of a compound of formula (II):



(II)

wherein X is a leaving group; with a compound of formula (III):



(III)

wherein R is as defined for formula (I), or a salt thereof;

in the presence of a base and an aqueous solvent; wherein the base is triethylamine, diisopropylamine, or a tetraC<sub>1-6</sub>alkylammonium hydroxide;

and optionally forming a pharmaceutically acceptable salt and/or hydrate thereof.

24. The process according to claim 23 wherein the base is triethylamine or a tetraC<sub>1-6</sub>alkylammonium hydroxide.

25. The process according to claim 23 wherein the base is triethylamine.

26. The process according to claim 23 wherein the base is tetrabutylammonium hydroxide or tetramethylammonium hydroxide.

27. The process according to claim 23 wherein the solvent is aqueous acetonitrile, an aqueous alcohol or water.

28. The process according to claim 23 wherein when the solvent is aqueous acetonitrile a ratio of between 0.7 and 1.4 acetonitrile:water is used.

29. The process according to claim 23 wherein the compound of formula (III) is 4-aminomethyl-3-methoxyiminopyrrolidinium dimethanesulfonate.

30. The process according to claim 23 wherein R is C<sub>1</sub> alkyl.